159 related articles for article (PubMed ID: 38479045)
1. Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis.
Makkawi S; Salamatullah HK; Alkhiri A; Faidah DE; Afif LM; Bukhari JI; Abulaban A; Al Malik Y; Levy M
Mult Scler Relat Disord; 2024 May; 85():105524. PubMed ID: 38479045
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
[TBL] [Abstract][Full Text] [Related]
4. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
5. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
[TBL] [Abstract][Full Text] [Related]
8. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
10. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
15. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Frampton JE
Drugs; 2020 May; 80(7):719-727. PubMed ID: 32266705
[TBL] [Abstract][Full Text] [Related]
18. Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials.
Xue T; Yu J; Chen S; Wang Z; Yang Y; Chen Z; Wang Z
Front Neurol; 2020; 11():604445. PubMed ID: 33391166
[No Abstract] [Full Text] [Related]
19. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
Crout TM; Parks LP; Majithia V
Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
[TBL] [Abstract][Full Text] [Related]
20. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
